Evolving Perspectives and Treatment Strategies in Chronic Spontaneous Urticaria - Episode 14

The Role of BTK Inhibitors in the Evolving CSU Treatment Landscape

Published on: December 6, 2024

Shawn Kwatra, MD, Naiem Issa, MD, PhD, Jennifer Hsiao, MD

Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors are reshaping the evolving treatment landscape for chronic spontaneous urticaria (CSU) by providing targeted therapeutic options that address underlying mast cell activation.

EP. 1: Bringing CSU Back Under The House of Dermatology

EP. 2: Understanding the Chronicity of CSU

EP. 3: The Psychosocial Impact of CSU

EP. 4: The Pathogenesis of CSU

EP. 5: Tips on Diagnosing CSU

EP. 6: Less Is More: Diagnostic Testing for CSU

EP. 7: Disease Severity and Delays in Treatment in CSU

EP. 8: The Role of Dermatologists in Treating CSU

EP. 9: Treatment Approaches and the Limitations of Antihistamines for CSU

EP. 10: Steroids and Immunosuppressive Agents for CSU

EP. 11: Novel Therapeutics in Development for CSU

EP. 12: The Role of BTK Inhibition in CSU

EP. 13: The Importance of Patient Education and Shared Decision-Making in CSU

Now Viewing

EP. 14: The Role of BTK Inhibitors in the Evolving CSU Treatment Landscape

EP. 15: Unmet Needs in CSU Management

EP. 16: Key Takeaways and Future Directions in CSU Care